Current Medical Research and Opinion最新文献

{"title":"Comorbidities of hypothyroidism.","authors":"Gabriela Brenta, Ulrike Gottwald-Hostalek","doi":"10.1080/03007995.2025.2476075","DOIUrl":"10.1080/03007995.2025.2476075","url":null,"abstract":"<p><p>Hypothyroidism is a relatively common condition that may affect as many as 10% of the population worldwide when its overt and subclinical presentations are considered. Important clinical comorbidities are highly prevalent in people with hypothyroidism and diminish quality of life and functional status in a manner that is proportional to the number of comorbidities present and their severity. This article reviews the common comorbidities of hypothyroidism, as reported in the literature. The comorbidities of hypothyroidism include clinical conditions commonly associated with hypothyroidism, such as dyslipidaemia, hypertension, fatigue or (possibly) cardiovascular disease, and can appear whether or not intervention with LT4 is applied appropriately to ensure biochemical euthyroidism. Other comorbidities may share some pathogenetic background with hypothyroidism, including depression or anxiety, or autoimmune conditions. Hypothyroidism may arise as a comorbidity of some other conditions, e.g. following the application of targeted cancer therapies or some disease-modfying treatments for multiple sclerosis. Other common treatments, including metformin, glucocorticoids or proton pump inhibitors, among others, may alter levels of thyrotropin, thus impacting on the monitoring of thyroid dysfunction and the diagnosis of thyroid dysfunction. Ensuring good control of hypothyroidism is a necessary first step in managing any patient with hypothyroidism. Then, physicians should be aware of the possibility of other comorbid conditions that must be addressed to achieve an optimal patient outcome.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-9"},"PeriodicalIF":2.4,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143596574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Economic burden of myasthenia gravis in China: a nationwide registry-based study.","authors":"Jiazhou Yu, Huanyu Zhang, Shanquan Chen, Dong Dong","doi":"10.1080/03007995.2025.2475075","DOIUrl":"https://doi.org/10.1080/03007995.2025.2475075","url":null,"abstract":"<p><strong>Background: </strong>The long-term treatment of myasthenia gravis (MG) and impaired productivity related to physical decline incur significant economic burdens on affected populations and society. This study aims to evaluate the costs of MG in China from a societal perspective and to identify the cost-driving factors.</p><p><strong>Methods: </strong>A web-based survey was conducted on 1020 MG patients recruited through a national registry system in China. Respondents reported their socio-demographic and disease-related information and annual expenses related to MG under direct medical and non-medical costs. Indirect costs were estimated among 268 working respondents based on hours of missed work and their annual income. Generalized linear models were used to identify factors associated with different categories of costs.</p><p><strong>Results: </strong>Among all respondents, the median annual direct medical cost was US$2219.0, with a median of $1860.2 contributed by medical costs and a median of $248.2 by non-medical costs. Higher education, unemployment, hospitalization, use of mechanical ventilation, and use of multiple medications were significant driving factors of direct medical and non-medical costs. Among respondents who are at least part-time employed, the indirect costs were generally minimal. Older age, physical burden of disease, and use of multiple medications were significant predictors of higher income loss.</p><p><strong>Conclusion: </strong>Population with MG in China reported heavy economic burdens related to medication. Disease severity is a major driving factor of both direct and indirect costs. Targeted policies are needed to alleviate the financial burden of MG on patients and society at large.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-7"},"PeriodicalIF":2.4,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adherence to mt-sDNA testing for colorectal cancer screening among new users in a US Black population.","authors":"Mallik Greene, Shrey Gohil, Mark Camardo, A Burak Ozbay, Paul Limburg, Jerry Lovelace","doi":"10.1080/03007995.2025.2475074","DOIUrl":"10.1080/03007995.2025.2475074","url":null,"abstract":"<p><strong>Objective: </strong>Colorectal cancer (CRC) poses significant mortality risks, particularly among Black individuals, who experience the highest CRC incidence and mortality rates in the United States. This study examined adherence to multi-target stool DNA (mt-sDNA) testing in this population.</p><p><strong>Methods: </strong>This retrospective cohort analysis used Exact Sciences Laboratories (ESL)-linked claims data from January 2017 to December 2023 on Black patients in the United States aged 45 and older. High-risk individuals, those with payers other than commercial plans, managed care organizations, Medicare Advantage, Medicaid, or Medicare, and individuals with mt-sDNA prescriptions outside the study period were excluded. Adherence was defined as the percentage of patients returning the test kit with valid results within 365 days of shipment. Logistic regression analysis was used to identify factors associated with adherence.</p><p><strong>Results: </strong>Among 434,951 patients included in the study, the overall adherence to mt-sDNA testing was 62.0% (<i>N</i> = 266,981), with a mean time to adherence of 27.6 days (SD = 44.17). Females, older adults (76+ years), and non-metropolitan residents had higher adherence than males, younger adults, and metropolitan patients (all <i>p</i> < 0.001), respectively. Patients with orders from GI specialists had higher adherence than other prescribing clinicians (NP/PA: OR = 0.39, OB/GYN: OR = 0.54, Other: OR = 0.38, PCP: OR = 0.50; all <i>p</i> < 0.001). Digital outreach, especially SMS and email combination, was also associated with higher adherence (OR = 1.25, <i>p</i> < 0.001).</p><p><strong>Conclusions: </strong>This large, national study found a 62.0% adherence rate to mt-sDNA testing among Black individuals. Higher adherence was associated with being female, older age, non-metropolitan residence, and digital outreach. While the findings highlight the promise of mt-sDNA, further research is needed to explore its full potential in improving CRC screening adherence across different demographic groups.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-8"},"PeriodicalIF":2.4,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143540326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Web references are not eternal: time-trend and qualitative impact of the loss of access to online resources cited in peer-reviewed medical journals.","authors":"Benjamin Lemaire, Fanélie Bauer, Elena Chaves Rodriguez, Jonathan Ghesquiere, Amandine Radziejwoski, Aurélie Roth, Maud Boyer","doi":"10.1080/03007995.2025.2475091","DOIUrl":"10.1080/03007995.2025.2475091","url":null,"abstract":"<p><strong>Objective: </strong>Web resources can contain high-quality data relevant to peer-reviewed medical publications. However, their online location may change or disappear with time. As medical publication professionals, we are concerned with the ephemeral nature of web resources and the associated qualitative impact on publication integrity of referencing such resources.</p><p><strong>Methods: </strong>Time-dependence of the phenomenon was probed using a dataset of reference lists from open and free access articles published in 2018. Each reference list was manually screened to tally the number of web pages no longer accessible. The analysis was repeated yearly from 2021 to 2023. Additionally, a set of proofs was analyzed to investigate the proportion of cited web references already inaccessible at publication. A third dataset, consisting of modeling articles published in 2018-2023, was used to quantify -at a single timepoint- the share of web resources cited as model inputs that were inaccessible.</p><p><strong>Results: </strong>The proportion of inaccessible web resources increased on average from 27.2% to 41.9% three to five years post publication (<i>n</i> = 992 articles), respectively. One out of four analyzed proofs cited at least one inaccessible web resource (<i>n</i> = 50). Five years after publication, 26.1% of web resources used as model inputs were no longer accessible, with one in three modeling articles being impacted (<i>n</i> = 61).</p><p><strong>Conclusion: </strong>The issue of inaccessible web resources cited in peer-reviewed medical publications is of great concern due to the fast pace and potential impact on research reproducibility. These findings call for the definition of best practices involving all stakeholders and the deployment of robust archiving solutions.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-6"},"PeriodicalIF":2.4,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143556192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of contraceptive use and side effects among women in five countries across the Middle East: a cross-sectional study.","authors":"Azza Ramadan, Anan S Jarab, Ahmad Z Al Meslamani, Hebatallah Ahmed Mohamed Moustafa, Amira B Kassem, Abuelnor Mohammed, Wael Osman, Reem Ibrahim, Karem H Alzoubi","doi":"10.1080/03007995.2025.2472907","DOIUrl":"10.1080/03007995.2025.2472907","url":null,"abstract":"<p><strong>Purpose: </strong>Contraceptive use and associated adverse effects are underreported in the Middle East. This study aimed to investigate contraceptive use and reported side effects in five Middle Eastern countries.</p><p><strong>Methods: </strong>This study, conducted over eight weeks in the UAE, Egypt, Jordan, Syria, and Iraq, utilized an online closed-ended structured questionnaire to extract the study information. Reproductive-age women were surveyed about hormonal and non-hormonal contraceptive usage practices, frequency, types, and severity of contraceptive-associated side effects. Logistic regression analysis was utilized to determine the predictors of the occurrence of side effects associated with contraceptive use.</p><p><strong>Results: </strong>The prevalence of contraceptive use was 81.2% (1069/1317). The most common contraceptive methods were combined oral contraceptive pills (46.6%, 511/1069), mini pills (15.4%, 169/1069), and hormonal loops (13.8%, 151/1069). The prevalence of contraceptive-associated side effects was 41.9% (448/1069). The commonly reported mild-to-moderate side effects were irregular menstrual bleeding (87.9%), headaches (88.2%), and mood changes (93.5%). Interestingly, the participants living in Egypt (AOR: 14.58, 95% CI: 4.67-45.53, <i>p</i> = 0.012) and Iraq (AOR: 25.71, 95% CI: 9.93-66.60, <i>p</i> = 0.001) had greater odds of developing contraceptive-related side effects than did their counterparts. Breastfeeding (AOR: 0.43, 95% CI: 0.20-0.92, <i>p</i> = 0.03), hypertension (AOR: 0.50, 95% CI: 0.26-0.99, <i>p</i> = 0.047), and smoking (AOR: 0.43, 95% CI: 0.20-0.90, <i>p</i> = 0.027) status reduced the risk of side effects. Surprisingly, healthcare follow-ups significantly increased the risk of side effects among contraceptive users (AOR: 3.48, 95% CI: 2.03-5.97; <i>p</i> = 0.001).</p><p><strong>Conclusion: </strong>Many contraceptive users reported experiencing side effects, which are predominantly mild to moderate. This underscores the need for improved patient education and follow-up, especially in Egypt and Iraq.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-10"},"PeriodicalIF":2.4,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143491166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction.","authors":"","doi":"10.1080/03007995.2025.2473240","DOIUrl":"https://doi.org/10.1080/03007995.2025.2473240","url":null,"abstract":"","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1"},"PeriodicalIF":2.4,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143514885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Indirect comparison of the relative vaccine effectiveness of mRNA-1283 vs. BNT162b2 vaccines against symptomatic COVID-19 among US adults.","authors":"Ekkehard Beck, Mihaela Georgieva, Wei-Jhih Wang, Andres Gomez-Lievano, Hongjue Wang, Yipeng Gao, Hagit Kopel, Mary Bausch-Jurken, Oscar Patterson-Lomba, Fan Mu, Eric Wu, Nicolas VandeVelde","doi":"10.1080/03007995.2025.2466726","DOIUrl":"https://doi.org/10.1080/03007995.2025.2466726","url":null,"abstract":"<p><strong>Background: </strong>COVID-19 continues to pose a significant health burden, particularly among older adults. mRNA-1283 is a next-generation COVID-19 mRNA vaccine developed to enhance immune response. Findings from the Phase 3 NextCOVE trial comparing bivalent versions of mRNA-1273 and mRNA-1283 vaccines have recently become available. However, there are no head-to-head trials comparing mRNA-1283 and the BNT162b2 vaccine.</p><p><strong>Objective: </strong>To indirectly compare the effectiveness of mRNA-1283 and BNT162b2 against symptomatic COVID-19 among adults in the U.S.</p><p><strong>Methods: </strong>A targeted literature review was conducted to identify relevant studies comparing the mRNA-1273 and BNT162b2 bivalent vaccines. A real-world evidence (RWE) study by Kopel et al. (2023) assessing the relative vaccine effectiveness (rVE) of mRNA-1273 vs. BNT162b2, was selected for an indirect treatment comparison (ITC) against the NextCOVE trial using the Bucher method. Analyses were stratified by age group, and sensitivity analyses were conducted using alternative outcome definitions.</p><p><strong>Results: </strong>Despite differences between NextCOVE and the Kopel study, comparability assessments supported a robust ITC. Among participants ≥18 years of age, the indirect rVE of mRNA-1283 vs. BNT162b2 against symptomatic COVID-19 was 15.3% (95% CI: 4.7-24.8%, p = 0.006). For adults ≥65 years of age, the rVE was 22.8% (95% CI: 3.7-38.1%, p = 0.022). Sensitivity analyses with alternative outcome definitions supported these estimates.</p><p><strong>Conclusion: </strong>This analysis provides consistent and statistically significant evidence indicating the next-generation mRNA-1283 vaccine is more effective in preventing symptomatic COVID-19 than BNT162b2, with the largest effect in individuals aged ≥65. Consistent results across sensitivity analyses underscore the robustness of the findings, offering important evidence to inform vaccination decisions by policymakers, providers, and payers.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-21"},"PeriodicalIF":2.4,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143457210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world prevalence of potential drug-drug interactions associated with oral advanced therapies indicated for ulcerative colitis.","authors":"Maryia Zhdanava, Sabree Burbage, Todor I Totev, Sumesh Kachroo, Lilian Diaz, Bridget Godwin, Patrick Lefebvre, Dominic Pilon","doi":"10.1080/03007995.2025.2465649","DOIUrl":"10.1080/03007995.2025.2465649","url":null,"abstract":"<p><strong>Objective: </strong>To describe potential drug-drug interactions (DDIs) with oral advanced therapies among patients with ulcerative colitis (UC) and characterize clinical assessments before ozanimod initiation.</p><p><strong>Methods: </strong>Adults with UC were selected from the Merative MarketScan Commercial Database (01 January 2018-31 January 2023); the index date was the most recent UC diagnosis. Patients had no other immune conditions in the 12-month baseline period before the index date. Those with moderate-to-severe UC were analyzed separately. Potential baseline DDIs were identified as claims for medications that may cause a moderate/severe DDI with Janus kinase (JAK) inhibitors (tofacitinib/upadacitinib) or ozanimod according to the Merative Micromedex Complete Drug Interactions Tool. Clinical assessments before ozanimod initiation were characterized.</p><p><strong>Results: </strong>Of 58,870 patients with UC, 24,654 (41.9%) had moderate-to-severe UC. All potential DDIs with ozanimod were severe, while JAK inhibitors had moderate and severe potential DDIs. Among patients with UC, mean (standard deviation) number of severe DDIs was 2.0 (2.4) for ozanimod and 0.2 (0.5) for JAK inhibitors; in moderate-to-severe UC, it was 2.3 (2.6) for ozanimod and 0.4 (0.6) for JAK inhibitors. The most common potential DDIs for ozanimod in UC and moderate-to-severe UC were ondansetron (18.6% and 22.7%), azithromycin (11.9% and 12.8%), as well as hydrocodone, fentanyl, albuterol, ciprofloxacin, and metronidazole (9.0%-11.0% each). For JAK inhibitors, these were COVID-19 vaccines (30.7% and 31.4%), infliximab (8.5% and 20.2%), fluconazole (6.1% and 6.8%), and azathioprine (5.5% and 13.0%). Among patients initiating ozanimod, the first claim for a required clinical assessment was on average, 8 months before initiation.</p><p><strong>Conclusion: </strong>Comorbidities and polypharmacy among patients with UC pose a high risk of DDIs for oral advanced therapies and required pre-treatment clinical assessments can be complicated. This justifies a thorough review of patient profiles for prescribers considering novel treatment options.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"329-338"},"PeriodicalIF":2.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143406119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improving the management of Polycythemia Vera patients eligible for cytoreduction: report of a multidisciplinary advisory board.","authors":"Francesco Ramundo, Elena Rossi, Ketty Peris, Alfredo Pontecorvi, Gabriele Sani, Silvia Betti, Marco Marietta, Valerio De Stefano","doi":"10.1080/03007995.2025.2458531","DOIUrl":"10.1080/03007995.2025.2458531","url":null,"abstract":"<p><strong>Introduction: </strong>The management of patients with Polycythemia Vera (PV) traditionally includes low-dose aspirin, phlebotomy, and cytoreductive therapy for high-risk individuals. Recent evidence suggests that cytoreductive treatment may be warranted for patients with additional risk factors beyond the traditional criteria of a history of thrombosis and age over 60 years. Introducing new therapeutic agents, including ropeginterferon alfa-2b and ruxolitinib, enables a more personalized treatment approach tailored to individual patient characteristics.</p><p><strong>Case report: </strong>This report presents three complex clinical scenarios involving patients with PV who required cytoreductive therapy, which were discussed by a multidisciplinary advisory board. Each case is accompanied by a concise literature review and recommendations from non-hematologist specialists on managing adverse events associated with cytoreductive treatment. A multidisciplinary expert panel has identified three conceptual pathways to guide clinicians in selecting cytoreductive therapies and managing their associated complications.</p><p><strong>Conclusion: </strong>The advent of new criteria for starting cytoreduction and the approval of novel drugs for PV has increased the complexity of selecting appropriate cytoreductive therapies. A multidisciplinary approach is increasingly essential to ensure personalized care that maximizes tolerability and minimizes adverse events, particularly given the often chronic nature of the treatment.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"239-245"},"PeriodicalIF":2.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143063887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of oral anticoagulants on mortality from pneumonia: a propensity score matching analysis.","authors":"Martin J Ryll, Isabell Aster, Aurelia Zodl, Sarah Thaler, Clemens Rieder, Roland Tomasi, Philipp Groene","doi":"10.1080/03007995.2025.2471498","DOIUrl":"10.1080/03007995.2025.2471498","url":null,"abstract":"<p><strong>Objective: </strong>Pneumonia continues to be one of the leading causes of death. During the COVID pandemic, pre-existing anticoagulant therapy with direct oral anticoagulants (DOACs) appeared to be beneficial. The present study aimed to investigate the impact of pre-existing DOAC therapy on mortality from community-acquired, non-COVID pneumonia.</p><p><strong>Methods: </strong>The study utilized data from the eICU Collaborative Research Database, a comprehensive, multi-institutional critical care database. We included all adult patients with community-acquired pneumonia, selecting for patients with a primary admission diagnosis of pneumonia or pulmonary sepsis who were admitted to the ICU <24 h after admission to the hospital. To adjust for confounders, we performed propensity score matching, matching patients receiving DOACs to an equivalent cohort of patients not receiving DOAC therapy. Our primary outcome was overall survival. Secondary outcomes included all-cause in-hospital mortality, all-cause in-ICU mortality, intubation within 24 h following ICU admission, incidence of acute kidney injury and renal replacement therapy, vasopressor administration, and mechanical ventilation days.</p><p><strong>Results: </strong>Our final matched cohort included 198 DOAC patients matched to 594 patients without DOAC therapy. Survival was significantly higher in DOAC patients with a hazard ratio of 0.56 [95% CI = 0.36-088]. Both all-cause in-unit mortality (6.1% [95% CI = 2.7-9.4%] vs. 13.3% [95% CI = 10.6-16.0%], <i>p</i> = 0.008) and all-cause in-hospital mortality (11.6% [95% CI = 7.2-16.1%] vs. 19.7% [95% CI = 16.5-22.9%], <i>p</i> = 0.013) were significantly lower in patients receiving DOACs.</p><p><strong>Conclusion: </strong>This study demonstrates a positive association between the pre-existing intake of direct oral anticoagulants and the survival of community acquired pneumonia. Future prospective studies should evaluate supportive therapy with DOACs.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"339-346"},"PeriodicalIF":2.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143522851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}